Delivery Order SPE2DB20D2104-SPE2DB25FMBTH

Award Date 11/10/24
Potential Completion Date 11/12/24
Potential Value $1.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on May 26, 2023. The $1,672.66 firm fixed-price delivery order is for the supply of 60 units of the drug Lubiprostone 24 MCG Capsule. The contract has a performance period through May 30, 2023 and does not have a set-aside designation. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a $3,804.60 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for 60 capsules of the medication Lubiprostone 24 MCG and has a completion date of January 18, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Lubiprostone 24 MCG Capsule 60s. The contract has a ceiling value of $1,299.26 and is a Firm Fixed Price Delivery Order. There was no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is also registered in the System for Award Management...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Lubiprostone 24 MCG Capsule 60S. The contract is a firm fixed price delivery order with a ceiling value of $2,042.65 and has a performance period through November 21, 2022. The award is not designated as a set-aside contract. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant...
This federal contract award to Amerisourcebergen Drug Corp, through its Corporate Office division, is a $10,784.78 firm fixed price delivery order from the Defense Logistics Agency (DLA) Troop Support Medical for the supply of 4557714344 - LUBIPROSTONE 8 MCG CAPSULE 60S. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC...
This contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Lubiprostone 24 MCG Capsules. The $2,891.20 firm-fixed-price delivery order was issued by the Defense Logistics Agency (DLA) and has an ultimate completion date of August 25, 2021. This order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. The IDC enables the DLA to efficiently...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Lubiprostone 24 MCG Capsule 60S, a pharmaceutical product. The $3,999.85 firm fixed price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of August 5, 2022. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
This federal contract award, valued at $14,745.81, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4554897024 - LUBIPROSTONE 24 MCG CAPSULE 60S, a pharmaceutical product. The award is a Delivery Order placed under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026....
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Lubiprostone 8 mcg capsules. The $1,297.56 firm-fixed-price contract has a completion date of September 9, 2022 and was awarded on September 8, 2022. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Lubiprostone 8 MCG Capsules. The $1,358.73 firm fixed-price contract has an ultimate completion date of October 19, 2021. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical. This IDC serves as the primary...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB25FMBTH
    Delivery Order

This federal contract award, valued at $1,298.73, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of 60 capsules of the drug Lubiprostone 24 MCG, with a completion date of November 12, 2024.

The contract is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains.

The contract award was not designated with a set-aside requirement, indicating open competition.

Generated 5/20/25, 2:14 PM